Biotech / mRNA

🔥 Moderna and Merck's Cancer Vaccine Cleared Phase 3. The Stock Doubled Before Anyone Saw the Numbers.

Moderna and Merck's personalized mRNA cancer vaccine cleared Phase 3 in 1,137 melanoma patients — and Moderna's stock more than doubled before the full numbers were even released.

By Tech Arcade··4 min read

Moderna and Merck's Cancer Vaccine Cleared Phase 3. The Stock Doubled Before Anyone Saw the Numbers. — Tech Arcade
Photo: Ed Us / Unsplash

On August 19, an independent monitoring board looked at data from 1,137 melanoma patients and told Moderna and Merck to stop the suspense: their personalized mRNA cancer vaccine, paired with Keytruda, had beaten Keytruda alone. Wall Street didn’t wait for the fine print. Moderna’s stock more than doubled that day — its best single session ever (Forbes).

Here’s the number that actually matters, and it’s older than this week’s headline. In the Phase 2b run that got everyone here, a 157-patient trial cut the risk of cancer coming back or killing the patient by 44% versus the standard of care (BioPharma Dive). The Phase 3 result confirms that wasn’t a fluke — at roughly seven times the patient count.

The catch, and it’s a real one: the companies haven’t released the Phase 3 efficacy figures yet. They told the world it worked and are saving the actual hazard ratios for a medical conference. So the market repriced a company on a press release. That’s the story — and the thesis: a made-to-order cancer shot just crossed the hardest bar in drug development, and the details we still don’t have are worth billions.

🧠 Why This Matters

Most vaccines teach your immune system to spot a virus. This one teaches it to spot your specific tumor. After surgeons remove a melanoma, scientists sequence it, hunt for the mutations that make those cancer cells look different from healthy ones, and build a custom mRNA recipe — up to 34 of these “neoantigen” targets per patient (Merck). Your cells read the recipe, flag the fingerprint, and your T-cells go hunting for any stray cancer cell left behind.

The reason this is a big deal isn’t the melanoma. It’s the platform. If you can turn a patient’s own tumor into a personalized vaccine on a repeatable manufacturing line, melanoma is just the first door. That’s why one Phase 3 readout moved a stock like a takeover rumor.

“This is the first Phase 3 study to show that intismeran, a treatment designed based on the unique mutational ‘fingerprint’ of a patient’s own tumor, given in combination with pembrolizumab can reduce the risk of recurrence or death.” — Professor Georgina Long, principal investigator (Merck)

📊 Deep Dive

The trial is called INTerpath-001. The drug, once known as mRNA-4157, now goes by intismeran autogene. Here’s what’s under the hood:

  • Patients: 1,137 people with completely resected Stage IIB–IV melanoma — the high-risk cases where the tumor is gone but the fear of return is not.
  • The regimen: intismeran at 1 mg every three weeks (up to 9 doses), layered on top of Keytruda at 400 mg (Merck).
  • What it hit: the primary endpoint (recurrence-free survival) and a key secondary endpoint (distant metastasis-free survival) — meaning fewer cancers came back, and fewer spread to distant organs.
  • Phase 2b precedent: 157 patients, a 44% reduction in recurrence-or-death risk over roughly three years (CNBC).
  • The reaction: Moderna shares more than doubled; Merck’s rose too. Jefferies analyst Andrew Tsai floated “billions of dollars in sales from the vaccine in melanoma alone” (BioPharma Dive).

Notice what’s missing from that list: the Phase 3 percentages. The monitoring board saw “statistically significant and clinically meaningful” improvement and greenlit the readout — but the companies are holding the exact numbers for a future medical meeting. You’re looking at a $100-billion-plus swing in market value built on the word “significant.”

⚠️ The Catch

Start with the obvious: topline is not the same as approved. No hazard ratios, no p-values, no FDA filing date. When those numbers arrive, they’ll either justify the run-up or deflate it, and history is littered with “met endpoints” press releases that looked thinner in the full dataset.

Then there’s the manufacturing problem. A one-size-fits-all pill rolls off a line by the million. A personalized vaccine has to be built one patient at a time — sequence the tumor, design up to 34 targets, synthesize the mRNA, ship it back — for every single person. That’s a logistics puzzle and a cost question rolled into one, and neither company has said what a course will cost or how fast they can turn one around.

And the 44% headline figure? It came from 157 patients. That’s a small deck to bet a franchise on, which is exactly why the Phase 3 mattered — and exactly why the still-hidden Phase 3 effect size is the number to wait for.

🎯 What Happens Next

Two clocks are ticking. The first is regulatory: expect the companies to take this data to the FDA, with the full efficacy numbers surfacing at an oncology conference before any approval. The second is the pipeline expansion — intismeran is already being tested in kidney, bladder, and non-small cell lung cancers (BioPharma Dive). If the melanoma win reads across to even one of those, the addressable market stops being a niche skin-cancer play and becomes something much larger.

For Moderna specifically, this is an identity shift. The company that became a household name on a COVID shot now has a credible second act that has nothing to do with a pandemic — and investors just told it so, in one trading session.

🧩 Bigger Picture

Follow the money and it points at Keytruda. That drug is Merck’s roughly $29.5-billion-a-year engine, and its patent protection starts eroding around 2028 (BioPharma Dive). A personalized vaccine that only works bolted onto Keytruda is a rather elegant way to keep patients — and revenue — tethered to the franchise well past the cliff. The combination is the moat.

TD Cowen’s Tyler Van Buren called it a “landmark moment.” (BioPharma Dive)

Zoom out and the shape is familiar: the same mRNA technology that raced a vaccine to market in a year is now being pointed at the disease that scares people most. The COVID shot proved the delivery system works at planetary scale. Cancer is the harder, more personal test — one tumor, one recipe, one patient at a time.

The vaccine cleared the trial. Now Moderna and Merck have to clear the part they haven’t shown you yet — and a doubled stock price is already daring them to.

Sources